Cargando…

Dose escalation via brachytherapy boost for nasopharyngeal carcinoma in the era of intensity-modulated radiation therapy and combined chemotherapy

To investigate if dose escalation using intracavitary brachytherapy (ICBT) improves local control for nasopharyngeal carcinoma (NPC) in the era of intensity-modulated radiation therapy (IMRT) and concurrent chemoradiation treatment (CCRT). We retrospectively analyzed 232 patients with Stage T1–3 N0–...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chao, Hsing-Lung, Liu, Shao-Cheng, Tsao, Chih-Cheng, Lin, Kuen-Tze, Lee, Steve P, Lo, Cheng-Hsiang, Huang, Wen-Yen, Liu, Ming-Yueh, Jen, Yee-Min, Lin, Chun-Shu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5737244/ https://www.ncbi.nlm.nih.gov/pubmed/28992206 http://dx.doi.org/10.1093/jrr/rrx034

Ejemplares similares

Novel application of stereotactic ablative radiotherapy using CyberKnife(®) for early-stage renal cell carcinoma in patients with pre-existing chronic kidney disease: Initial clinical experiences
por: LO, CHENG-HSIANG, et al.
Publicado: (2014)

Definitive radiotherapy dose escalation with chemotherapy for treating non-metastatic oesophageal cancer
por: Fan, Chao-Yueh, et al.
Publicado: (2018)

Image-guided interstitial brachytherapy boost for nasopharyngeal carcinoma: technical aspects
por: Murakami, Naoya, et al.
Publicado: (2020)

Successful Treatment of Infantile Fibrosarcoma Spinal Metastasis by Chemotherapy and Stereotactic Hypofractionated Radiotherapy
por: Lo, Cheng-Hsiang, et al.
Publicado: (2013)

Dose escalation in oropharyngeal cancer: a comparison of simultaneous integrated boost and brachytherapy boost
por: Embring, Anna, et al.
Publicado: (2023)

Comparisons of quality of life for patients with nasopharyngeal carcinoma after treatment with different RT technologies
por: JANG-CHUN, L., et al.
Publicado: (2014)

Survival and prognostic factors for patients with advanced hepatocellular carcinoma after stereotactic ablative radiotherapy
por: Lo, Cheng-Hsiang, et al.
Publicado: (2017)

Lower Urinary Tract Infection and Subsequent Risk of Prostate Cancer: A Nationwide Population-Based Cohort Study
por: Fan, Chao-Yueh, et al.
Publicado: (2017)

Long-Term Breast Cancer Patient Outcomes After Adjuvant Radiotherapy Using Intensity-Modulated Radiotherapy or Conventional Tangential Radiotherapy
por: Yang, Jen-Fu, et al.
Publicado: (2016)

Endoscope-Guided Interstitial Intensity-Modulated Brachytherapy and Intracavitary Brachytherapy as Boost Radiation for Primary Early T Stage Nasopharyngeal Carcinoma
por: Wan, Xiang-Bo, et al.
Publicado: (2014)

Influence of Metal of the Applicator on the Dose Distribution during Brachytherapy
por: Wu, Chin-Hui, et al.
Publicado: (2014)

Risk of second primary malignancies among patients with prostate cancer: A population-based cohort study
por: Fan, Chao-Yueh, et al.
Publicado: (2017)

HDR Brachytherapy Dose Distribution is Influenced by the Metal Material of the Applicator
por: Wu, Chin-Hui, et al.
Publicado: (2015)

Brachytherapy boost in loco-regionally advanced nasopharyngeal carcinoma: a prospective randomized trial of the International Atomic Energy Agency
por: Rosenblatt, Eduardo, et al.
Publicado: (2014)

New era of electronic brachytherapy
por: Ramachandran, Prabhakar
Publicado: (2017)

3D-image-guided HDR-brachytherapy versus 2D HDR - brachytherapy after external beam radiotherapy for early T-stage nasopharyngeal carcinoma
por: Ren, YuFeng, et al.
Publicado: (2014)

Intensity modulated radiotherapy with concurrent chemotherapy for larynx preservation of advanced resectable hypopharyngeal cancer
por: Huang, Wen-Yen, et al.
Publicado: (2010)

Phase I study of dose escalation to dominant intraprostatic lesions using high-dose-rate brachytherapy
por: Chapman, Christopher H, et al.
Publicado: (2018)

Boost in radiotherapy: external beam sunset, brachytherapy sunrise
por: Maciejewski, Boguslaw
Publicado: (2009)

Adjuvant radiotherapy with brachytherapy boost in soft tissue sarcomas
por: Cortesi, Annalisa, et al.
Publicado: (2017)

Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible
por: Lee, Tae Hoon, et al.
Publicado: (2021)

Stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the treatment of hepatocellular carcinoma with portal vein invasion: a retrospective analysis
por: Yang, Jen-Fu, et al.
Publicado: (2019)

Gene-associated methylation status of ST14 as a predictor of survival and hormone receptor positivity in breast Cancer
por: Dai, Yang-Hong, et al.
Publicado: (2021)

Radiosensitivity index emerges as a potential biomarker for combined radiotherapy and immunotherapy
por: Dai, Yang-Hong, et al.
Publicado: (2021)

Conventional dose versus dose escalated radiotherapy including high-dose-rate brachytherapy boost for patients with Gleason score 9–10 clinical localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2022)

Unexpected lower biochemical control of high-dose-rate brachytherapy boost than low-dose-rate brachytherapy boost for clinically localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2020)

Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: A care-compliant case report
por: Lin, Young-Hsiang, et al.
Publicado: (2016)

Brachytherapy for malignancies of the vagina in the 3D era
por: Glaser, Scott M., et al.
Publicado: (2015)

Response to ‘Unexpected lower biochemical control of high-dose-rate brachytherapy boost than low-dose-rate brachytherapy boost for clinically localized prostate cancer’
por: Slevin, Finbar, et al.
Publicado: (2020)

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer
por: Ma, Cheng-Jen, et al.
Publicado: (2017)

UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI
por: Hsieh, Yi-Chien, et al.
Publicado: (2021)

Results of a Prospective Dose Escalation Study of Linear Accelerator–Based Virtual Brachytherapy (BOOSTER) for Prostate Cancer; Virtual HDR Brachytherapy for Prostate Cancer
por: Eade, Thomas, et al.
Publicado: (2019)

Long-Term Outcomes of Three-Dimensional High-Dose-Rate Brachytherapy for Locally Recurrent Early T-Stage Nasopharyngeal Carcinoma
por: Lin, Yanzhu, et al.
Publicado: (2019)

The interplay of host genetic factors and Epstein-Barr virus in the development of nasopharyngeal carcinoma
por: Lung, Maria Li, et al.
Publicado: (2014)

CyberKnife Boost for Patients with Cervical Cancer Unable to Undergo Brachytherapy
por: Haas, Jonathan Andrew, et al.
Publicado: (2012)

High-dose-rate brachytherapy boost for prostate cancer: rationale and technique
por: Morton, Gerard C.
Publicado: (2014)

Tumor bed boost in breast cancer: Brachytherapy versus electron beam
por: Roy, Sanjoy, et al.
Publicado: (2013)

Interstitial high-dose rate brachytherapy as boost for anal canal cancer
por: Falk, Alexander Tuan, et al.
Publicado: (2014)

Brachytherapy boost after chemoradiation in anal cancer: a systematic review
por: Frakulli, Rezarta, et al.
Publicado: (2018)

Predictable biomarkers of developing lymphoma in patients with Sjögren syndrome: a nationwide population-based cohort study
por: Chiu, Yu-Hsiang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fco93ocknu3u0spor73lhi7lvd